Managing Cash Flow And Financial Risk For Cell And Gene Therapies

Since the first CAR-T therapy product approval in 2017, cell and gene therapies have held great potential to transform treatment for cancer and other complex diseases. However, the personalized manufacturing process for each treatment and specialized administration and logistics requirements create cost-related burdens for both patients and hospitals.

Hospitals have been slow to start administering CAR-T therapies, due in large part to the financial and reimbursement challenges related to the products. Pharmaceutical manufacturers must now take steps to expand access to these therapies and mitigate financial risk for providers. Companies that are able to provide a high level of coordination and financial processes that ease cash flow burdens for sites of care will stand out as preferred partners in an increasingly competitive industry.